PRESS RELEASES
Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LAD Data support the start of a…
FAVORABLE SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES VALIDATE AND SIGNIFICANTLY DE-RISK THE PROGRAM SUPPORTS THE FEASIBILITY OF INTRAVENOUS AND SUBCUTANEOUS DOSING REGIMENS IN UPCOMING CLINICAL…
JJP Biologics confirms the mechanism of action and immunostimulatory activity of JJP-1008, a potential first-in-class therapeutic anti-CD270 monoclonal antibody. JJP-1008 selectively inhibits the immunosuppressive activity…
JJP Biologics confirms the mechanism of action and immunostimulatory activity of JJP-1008, a potential first-in-class therapeutic anti-CD270 monoclonal antibody. JJP-1008 selectively inhibits the immunosuppressive activity…
JJP Biologics announces the start of the MAD part in the ongoing Phase I Clinical Trial of a new investigational medicinal product JJP-1212, a first-in-class…
JJP Biologics announces initiation of the development of an active substance & drug product manufacturing process for a first-in-class anti-CD270 monoclonal antibody (JJP-1008) aimed at…